Charles Nguyen, MD, of University of Michigan, explains the design, importance, and potential implications of a phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
FORTUNE: Tivozanib Plus Nivolumab for Advanced nccRCC
By Charles Nguyen, MD - Last Updated: June 20, 2024Post Tags:ASCO 2024: Focus on Renal Cell Carcinoma
Related Posts
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.